

Lenacapavir with Fostemsavir in a multi-drug resistant HIV-infected hemodialysis patient

P. Clevenbergh¹, F. Bigirimana¹, Sigi Van Den Wijngaert², C. Fosso¹, Karolien Stoffels², Charlotte Martin³, and E. Maillart¹

¹UVC Brugmann

²Vrije Universiteit Brussel Vakgroep Huisartsgeneeskunde

³Centre Hospitalier Universitaire Saint-Pierre

July 28, 2023

Abstract

We report an hemodialysis MDR HIV-infected patient switched to fostemsavir with lenacapavir plus lamivudine for more than a year. She maintained a suppressed viral replication and didn't present any clinical or biological drug-related side effects. The combination of lenacapavir plus fostemsavir looks promising in terms of safety and efficacy even in patients with end-stage renal disease awaiting renal transplant. Both drugs are first in class ARVs so that there is no cross resistance with previous drugs, maintaining their efficacy against MDR HIV.

Hosted file

FTR - LEN FINAL VERSION.docx available at <https://authorea.com/users/349031/articles/657192-lenacapavir-with-fostemsavir-in-a-multi-drug-resistant-hiv-infected-hemodialysis-patient>